The results of the current study support the hypothesis that the mild clinical presentations of pediatric COVID-19 are driven by the expression of critical biogenomic markers, specifically the first-phase receptor genes (ACE2 and ANPEP) and second-phase receptor genes (EGFR and IGF2R). This evidence concerns the gene ANPEP and COVID-19.